Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Rap1 in the VMH regulates glucose homeostasis
Kentaro Kaneko, Hsiao-Yun Lin, Yukiko Fu, Pradip K. Saha, Ana B. De la Puente-Gomez, Yong Xu, Kousaku Ohinata, Peter Chen, Alexei Morozov, Makoto Fukuda
Kentaro Kaneko, Hsiao-Yun Lin, Yukiko Fu, Pradip K. Saha, Ana B. De la Puente-Gomez, Yong Xu, Kousaku Ohinata, Peter Chen, Alexei Morozov, Makoto Fukuda
View: Text | PDF
Research Article Metabolism Neuroscience

Rap1 in the VMH regulates glucose homeostasis

  • Text
  • PDF
Abstract

The hypothalamus is a critical regulator of glucose metabolism and is capable of correcting diabetes conditions independently of an effect on energy balance. The small GTPase Rap1 in the forebrain is implicated in high-fat diet–induced (HFD-induced) obesity and glucose imbalance. Here, we report that increasing Rap1 activity selectively in the medial hypothalamus elevated blood glucose without increasing the body weight of HFD-fed mice. In contrast, decreasing hypothalamic Rap1 activity protected mice from diet-induced hyperglycemia but did not prevent weight gain. The remarkable glycemic effect of Rap1 was reproduced when Rap1 was specifically deleted in steroidogenic factor-1–positive (SF-1–positive) neurons in the ventromedial hypothalamic nucleus (VMH) known to regulate glucose metabolism. While having no effect on body weight regardless of sex, diet, and age, Rap1 deficiency in the VMH SF1 neurons markedly lowered blood glucose and insulin levels, improved glucose and insulin tolerance, and protected mice against HFD-induced neural leptin resistance and peripheral insulin resistance at the cellular and whole-body levels. Last, acute pharmacological inhibition of brain exchange protein directly activated by cAMP 2, a direct activator of Rap1, corrected glucose imbalance in obese mouse models. Our findings uncover the primary role of VMH Rap1 in glycemic control and implicate Rap1 signaling as a potential target for therapeutic intervention in diabetes.

Authors

Kentaro Kaneko, Hsiao-Yun Lin, Yukiko Fu, Pradip K. Saha, Ana B. De la Puente-Gomez, Yong Xu, Kousaku Ohinata, Peter Chen, Alexei Morozov, Makoto Fukuda

×

Figure 2

Improved glucose homeostasis in Rap1ΔSF1 mice.

Options: View larger image (or click on image) Download as PowerPoint
Improved glucose homeostasis in Rap1ΔSF1 mice.
(A) Representative images...
(A) Representative images (original magnification, ×100; inset, original magnification, ×180) and quantification of Rap1 immunoreactivity in the hypothalamus of Rap1ΔSF1 mice and control mice. The number of Rap1-positive cells in the ARC and the VMH was counted and is represented as a fold change relative to control (n = 3). (B) Representative Western blots and densitometric quantification of VMH Rap1 expression normalized to β-actin. (n = 7–8/group). See complete unedited blots in the supplemental material. (C–E) Glucose profiles of Rap1ΔSF1 or control mice under normal chow conditions. Blood glucose (C, n = 6–15), glucose tolerance testing (D, n = 8), and insulin tolerance testing (E, n = 8) were measured. (F–H) Glucose profiles of HFD-fed Rap1ΔSF1 or control mice (14 weeks of HFD feeding, n = 6–7). Glucose (F), glucose tolerance testing (G), and insulin tolerance testing (H). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 for 2-tailed t tests (A–C and F) or 2-way ANOVA followed by Bonferroni’s multiple comparisons tests (D, E, G, and H). All error bars are mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts